This is a StreetInsider.com Premium Only Page

Histogenics (HSGX) – Press Releases

Nov 21, 2019 07:00 AM Entera Bio Establishes U.S. Headquarters and Announces Jonathan Lieber as Chief Financial Officer

Sep 30, 2019 07:30 AM Ocugen Announces Completion of its Merger with Histogenics to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics

Sep 26, 2019 04:25 PM Histogenics Corporation Announces Approval of Merger by Stockholders at Special Meeting

Sep 12, 2019 09:15 AM Histogenics Corporation Announces Adjournment of its Special Meeting to Thursday, September 26, 2019

Sep 11, 2019 04:05 PM Histogenics Corporation Announces Intent to Convene and Adjourn Its Special Meeting

Apr 24, 2019 08:30 AM X4 Pharmaceuticals Appoints E. Lynne Kelley, M.D. as Chief Medical Officer

Apr 8, 2019 07:00 AM Histogenics and Ocugen Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics

Feb 12, 2019 08:00 AM Jonathan Lieber Joins Danforth Advisors as Managing Director

Dec 21, 2018 04:05 PM Histogenics and FDA Conclude Discussions Regarding NeoCart® Phase 3 Clinical Trial Data and Regulatory Pathway

Nov 29, 2018 08:30 AM Histogenics and FDA Continue to Discuss NeoCart® Phase 3 Clinical Trial Data and Potential Regulatory Pathway

Nov 8, 2018 06:30 AM Histogenics Corporation Announces Third Quarter 2018 Financial and Operating Results

Nov 1, 2018 04:05 PM Histogenics and FDA to Continue Discussions on NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway

Oct 25, 2018 04:15 PM Histogenics Corporation to Report Third Quarter 2018 Financial Results on November 8, 2018

Oct 10, 2018 04:01 PM Histogenics Corporation Announces Closing of Public Offering of Common Stock and Warrants

Oct 5, 2018 08:10 AM Histogenics Corporation Announces Pricing of Public Offering of Common Stock and Warrants

Oct 4, 2018 04:01 PM Histogenics Corporation Announces Proposed Public Offering of Common Stock and Warrants

Sep 26, 2018 04:05 PM Histogenics to Meet With FDA to Discuss NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway

Sep 5, 2018 05:00 AM Histogenics Announces Top-Line Results From Phase 3 Clinical Trial of NeoCart® in Patients With Knee Cartilage Damage

Aug 9, 2018 06:30 AM Histogenics Corporation Announces Second Quarter 2018 Financial and Operating Results

Jul 31, 2018 08:00 AM Histogenics Corporation Appoints E. Lynne Kelley, M.D., FACS As Chief Medical Officer

Jul 26, 2018 08:30 AM Histogenics Corporation to Report Second Quarter 2018 Financial Results on August 9, 2018

Jul 25, 2018 04:15 PM Histogenics Corporation to Present at Canaccord Genuity’s 38th Annual Growth Conference

Jul 23, 2018 08:30 AM Histogenics Chief Operating Officer, Stephen Kennedy Appointed to Advanced Regenerative Manufacturing Institute’s Technology Advisory Sub-Committee

May 31, 2018 08:30 AM Histogenics Corporation to Host Investor Day on June 19, 2018

May 10, 2018 06:30 AM Histogenics Corporation Announces First Quarter 2018 Financial and Operating Results

Apr 26, 2018 08:30 AM Histogenics Corporation to Report First Quarter 2018 Financial Results on May 10, 2018

Apr 18, 2018 08:30 AM Histogenics Corporation Announces the Appointment of Susan Washer to Its Board of Directors

Mar 28, 2018 08:30 AM Histogenics Corporation to Present at Upcoming Investor Conferences

Mar 19, 2018 08:30 AM Histogenics Corporation to Present at Needham & Company’s 17th Annual Healthcare Conference

Mar 15, 2018 06:00 AM Histogenics Corporation Announces Financial and Operating Results for the Fourth Quarter and Year Ended December 31, 2017

Mar 2, 2018 08:30 AM Histogenics to Showcase NeoCart® at American Academy of Orthopedic Surgeons and Orthopedic Research Society 2018 Annual Meetings

Mar 1, 2018 08:30 AM Histogenics Corporation to Report 2017 Financial Results on March 15, 2018

Feb 20, 2018 08:30 AM Histogenics Corporation to Present at Upcoming Investor Conferences

Jan 25, 2018 04:05 PM Histogenics Corporation Announces Closing of Underwritten Registered Direct Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

Jan 22, 2018 06:59 PM Histogenics Corporation Announces Pricing of Underwritten Registered Direct Offering of 2,340,430 Shares of Common Stock

Jan 9, 2018 08:30 AM Histogenics Corporation Announces Receipt of $10 Million Up-front Payment for Japanese Neocart Agreement

Dec 21, 2017 06:00 AM Histogenics Corporation and MEDINET Co., Ltd Enter Into Licensing Agreement for Development and Commercialization of NeoCart for the Japanese Market

Nov 9, 2017 06:30 AM Histogenics Corporation Announces Third Quarter 2017 Financial and Operating Results

Oct 26, 2017 08:30 AM Histogenics Corporation to Report Third Quarter 2017 Financial Results on November 9, 2017

Oct 12, 2017 09:00 AM Histogenics Corporation Promotes Stephen Kennedy to Executive Vice President & Chief Operating Officer

Oct 2, 2017 04:15 PM Histogenics Announces Publication of Additional Biomechanical Data From Human Engineered Cartilage Testing

Sep 26, 2017 08:30 AM Histogenics Corporation to Present at the 2017 Cell & Gene Meeting on the Mesa

Aug 24, 2017 08:30 AM Histogenics Corporation to Present at Upcoming Investor Conferences

Aug 10, 2017 06:30 AM Histogenics Corporation Announces Second Quarter 2017 Financial and Operating Results

Jul 27, 2017 08:30 AM Histogenics Corporation to Announce Second Quarter 2017 Financial Results on August 10, 2017

Jul 26, 2017 08:30 AM Histogenics Corporation to Present at the 37th Annual Canaccord Genuity Growth Conference

Jul 11, 2017 08:30 AM Histogenics Announces Publication of Data From Collagen and Chondrocyte 3-D Bioprinting Study

Jun 27, 2017 04:01 PM Histogenics Completes Enrollment for Phase 3 Clinical Trial of Neocart® to Treat Knee Cartilage Damage

Jun 5, 2017 08:30 AM Histogenics Corporation Announces the Appointment of Donald Haut, Ph.D. as Chief Business Officer

May 16, 2017 08:30 AM Histogenics Corporation to Present at Upcoming Industry Conferences